FDA Determines Regulatory Review Period for EFFIENT Patent Extension

Summary

The Food and Drug Administration (FDA) has determined the regulatory review period for the patent extension of the human drug product EFFIENT, as required by law. The FDA made this determination following a submission to the Director of Patents and Trademarks, Department of Commerce, for the extension of the patent.